Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Company Profiles: Janssen Inc
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Company Profiles: Janssen Pharmaceuticals Inc
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Company Profiles: Janssen Biotech, Inc
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Company Profiles: Xian-Janssen Pharmaceutical Ltd
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Company Profiles: Janssen Pharmaceutical KK.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Company Profiles: Janssen Pharmaceutica NV.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
EPA's 33/50 Program Company Profile
Author:
Publisher:
ISBN:
Category : Aerospace industries
Languages : en
Pages : 156
Book Description
Publisher:
ISBN:
Category : Aerospace industries
Languages : en
Pages : 156
Book Description
NAMZARIC Drug Profile, 2023
Author: DrugPatentWatch
Publisher: DrugPatentWatch.com
ISBN: 1934899704
Category : Medical
Languages : en
Pages : 114
Book Description
Publisher: DrugPatentWatch.com
ISBN: 1934899704
Category : Medical
Languages : en
Pages : 114
Book Description
NAMZARIC Drug Profile, 2023
This report focuses on NAMZARIC and covers the following critical aspects of this drug:
- United States patents
- Expired United States patents
- FDA Paragraph IV patent challenges
- District Court patent litigation
- Patent Trial and Appeal Board (PTAB) patent cases
- European supplementary protection certificates (SPCs)
- Clinical trials
- Drug prices
- Finished product suppliers
- Raw active pharmaceutical ingredient (API) sources
NUCYNTA ER Drug Profile, 2023
Author: DrugPatentWatch
Publisher: DrugPatentWatch.com
ISBN: 1934899631
Category : Medical
Languages : en
Pages : 153
Book Description
Publisher: DrugPatentWatch.com
ISBN: 1934899631
Category : Medical
Languages : en
Pages : 153
Book Description
NUCYNTA ER Drug Profile, 2023
This report focuses on NUCYNTA ER and covers the following critical aspects of this drug:
- United States patents
- Expired United States patents
- FDA Paragraph IV patent challenges
- District Court patent litigation
- Patent Trial and Appeal Board (PTAB) patent cases
- European supplementary protection certificates (SPCs)
- Clinical trials
- Drug prices
- Finished product suppliers
- Raw active pharmaceutical ingredient (API) sources
Company Profiles: S.C. Johnson & Son, Inc
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description